Recent analyst upgrades and articles like this have provided a boost for Arena Pharmaceutical shares.
http://finance.yahoo.com/news/major-revenue-losses-patent-expirations-132000024.html
See disclaimers in the side bar. This is not an endorsement for any company, or investment in any company.
Disclosure: the author and family members are long shares of ARNA. The author has no position in VVUS.
Tuesday, January 15, 2013
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment